Search Press releases Keywords From To 10 Dec 2019 UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting Read More 6 Dec 2019 Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira[®] Read More 15 Nov 2019 Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study Read More 8 Nov 2019 Transparency notifications BlackRock, Inc. Read More 8 Nov 2019 UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP Read More 18 Oct 2019 Transparency notification Vanguard Health Care Fund Read More Pagination First page Previous page Previous … Page 60 Page 61 Page 62 Page 63 Current page 64 Page 65 Page 66 Page 67 Page 68 … Page 64 of 73 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
